[1] YOUNG RH,SCULLY RE.Ovarian Sertoli-Leydig cell tumors.A clinicopathological analysis of 207 cases[J].Am J Surg Pathol,1985,9(8):543-569.
[2]The WHO Classification of Tumours Editorial Board.Female genital tumours WHO classification of tumours[M].5th Edition.Lyon(France):International Agency for Research on Cancer,2020:113-115.
[3]郑文新,沈丹华,郭东辉,等.妇产科病理学[M].北京:科学出版社,2021,10:909.
ZHENG WX,SHEN DH,GUO DH,et al.Gynecologic and obstetric pathology[M]. Beijing:Science Publishing House,2021,10:909.
[4]YOUNG RH.Ovarian sex cord-stromal tumours and their mimics[J].Pathology,2018,50(1):5-15.
[5]MCCLUGGAGE WG,YOUNG RH.Ovarian Sertoli-Leydig cell tumors with pseudoendometrioid lubules (pseudoendometrioid Sertoli-leydigcell tumors)[J].Am J Surg Pathol,2007,31(4):592-597.
[6]RATHI M,BUDANIASK,KHALIDM,et al.Bilateral retiform variant of Sertoli Leydig cell tumour of ovary:an uncommon tumor with review of literature[J].Midlife Health,2015 6(1):35-38.
[7] YOUNG RH,PRAT J,SCULLY RE.Ovarian Sertoli-Leydig cell tumors with hete-rologous elements.I.Gastrointestinal epithelium and carcinoid:aclinicopathologic analysis of thirty-six cases[J].Cancer,1982,50(11):2448-2456.
[8] FLEMING NI,KNOWER KC,LAZARUS KA,et al.Aromatase is a direct target of FOXL2:C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter[J] PLOS One,2010,5(12):e14389.
[9]KOCK DE,TERZIC T,MCCLUGGAGE WG,et al.DICER1 mutations are consistently presentin moderately and poorly differentiated Sertoli-Leydig cell tumors[J].Am J Surg Pathol,2017,41(9):1178-1187.
[10] KARNEZIS AN,WANG Y,KEUL J,et al.DICER1 and FOXL2 mutation status correlates with clinicopathologic features in ovarian Sertoli-Leydig cell tumors[J].Am J Surg Pathol,2019,43(5):628-638.
[11] KATO N,KUSUMI T,KAMATAKI A,et al.DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors:a potential association with androgenic effects[J].Hum Pathol,2017,59:41-47.
[12]丁彩霞,李志斌,袁勇,等.卵巢支持-间质细胞瘤6例临床病理分析[J].现代肿瘤医学,2019,27(23):4264-4268.
DING SX,LI ZB,YUAN Y,et al.Clinical and pathologic analysis of six cases of sertoli-leydig cell tumor in ovary[J].Modern Oncology,2019,27(23):4264-4268.
[13] BEKKER P,MILAND-SAMUELSEN AR,SMERDEL MP,et al.Sertoli-Leydig cell tumor:a clinicopathological analysis in a comprehensive,national cohort[J].Gynecol Cancer,2023,4,33(12):1921-1927.
[14]杜心,林旭勇.卵巢支持-间质细胞瘤12例临床病理分析[J].中国医药指南,2018,16(34):108-109.
DU X,LIN XY.Clinical and pathologic analysis of twelve cases of sertoli-leydig cell tumor in ovary[J].Guide of China Medicine,2018,16(34):108-109.
[15]NEF J,HUBER DE.Ovarian Sertoli-Leydig cell tumours:A systematic review of relapsed cases[J].Obstet Gynecol Reprod Biol,2021,263:261-274.
[16]湛丽,宋光耀.中分化卵巢支持-间质细胞瘤8例临床病理分析[J].中国现代药物应用,2014,8(23):44-45.
ZHAN L,SONG GY.Clinical and pathologic analysis of eight cases of moderately differentiated sertoli-leydig cell tumor in ovary[J].Chinese Journal of Morden Drug Application,2014,8(23):44-45.
[17]GUO Y,WANG J.Ovarian Stertoli-Leydig cell tumors:an analysis of 13 cases[J].Archives of Gynecology and Obstetrics,2020,302(1):203-208.
[18]尹晓娇,宗珊,董鹤,等.巨大卵巢支持间质细胞瘤伴异源性成分1例[J].广东医学,2016,37(22):3366.
YIN XJ,ZONG S,DONG H,et al.One case of giant ovarian Sertoli-Leydig cell tumors with heterologous elements[J].Guangdong Medical Journal,2016,37(22):3366.